Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 50 Debt-to-Equity is 0.75 as of Dec. 2025, which is 14% above its 10-year median of 0.66. GuruFocus rates LSE:SPEC with a GF Score™ of 50/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Inspecs Group ranks worse than 79.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Inspecs Group's Debt-to-Equity or its related term are showing as below:
LSE:SPEC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.55 Med: 0.66 Max: 2.28
Current: 0.75
During the past 10 years, the highest Debt-to-Equity Ratio of Inspecs Group was 2.28. The lowest was 0.55. And the median was 0.66.
LSE:SPEC's Debt-to-Equity is ranked worse than 79.43% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs LSE:SPEC: 0.75
Inspecs Group (LSE:SPEC) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Inspecs Group Debt-to-Equity Related Terms
Inspecs Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SPEC vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (LSE:SPEC) has a Debt-to-Equity of 0.75 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Inspecs Group and its competitors. This is 14% above median its historical median of 0.66. Over the past decade, Inspecs Group's Debt-to-Equity has ranged from 0.55 to 2.28. According to the industry distribution chart, Inspecs Group ranks #560 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 79.4%.
Is Inspecs Group's Debt-to-Equity too high?
Inspecs Group's current Debt-to-Equity of 0.75 is 14% above median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 2.28. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Inspecs Group's value of 0.75 is 226.1% above this industry median. Based on the distribution chart, Inspecs Group ranks #560 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Inspecs Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #560 out of 705 companies for Debt-to-Equity. This places Inspecs Group in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Inspecs Group's value of 0.75 is 226.1% above this benchmark. Historically, Inspecs Group's own Debt-to-Equity has ranged from 0.55 to 2.28 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 0.23, Inspecs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current Debt-to-Equity of 0.75 is 226.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Debt-to-Equity is 0.75, which is 14% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.96 — trading 65.5% above its estimated fair value. The current Debt-to-Equity is 0.75, which is 14% above median its 10-year median of 0.66 and 226.1% above the Medical Devices & Instruments industry median of 0.23. Inspecs Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current Debt-to-Equity is 0.75 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.96 is trading 65.5% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
Debt-to-Equity: 0.75 (14% above median its 10-year median of 0.66)
GF Value™: £0.58 vs. price of £0.96 (65.5% above fair value)
Industry Position: 226.1% above the Medical Devices & Instruments median (#560 of 705)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
50GF Score
Get the complete analysis for LSE:SPEC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
